Author’s response to reviews

Title: Early risk assessment of circulating endothelial progenitor cells and plasma stromal cell-derived factor-1 for nondisabling ischemic cerebrovascular events

Authors:

wang zhao (zw13617681318@163.com)
Juan Liao (Liaojuan55@163.com)
Libo Zhao (zhaolibo@126.com)
Lanying He (helanyin99@163.com)
Yong Luo (666DUODUO@163.com)

Version: 1 Date: 01 Jan 2019

Author’s response to reviews:

Dear Editor and Reviewers:

Thank you for your letter and for the reviewers’ comments concerning our manuscript entitled “Early risk assessment of circulating vascular endothelial progenitor cells and plasma stromal cell-derived factor-1 on nondisabling ischemic cerebrovascular events” (ID: NURL-D-18-00725). Those comments are all valuable and very helpful for revising and improving our paper, as well as the important guiding significance to our researches. We have studied comments carefully and have made correction which we hope meet with approval. Revised portion are marked in red in the paper. The main corrections in the paper and the responds to the reviewer’s comments are as flowing:

Responds to the reviewer’s comments:

Reviewer #1:

1. Response to comment: The manuscript needs English editing throughout.

Response: We have professional help in revising this manuscript by American Journal Experts, and plus page number.
2. Response to comment: Materials and Methods need to be revised.

Response: We have re-written this part according to the reviewer’s suggestion. We are very sorry for our incorrect writing of dosage unit, MTT and Transwell assays were performed as described by Zeng et al.

3. Response to comment: The section of results was poor presented.

Response: We have revised this section.

4. Response to comment: The section of discussion was poor presented.

Response: We have revised this section, two references has been added.

Special thanks to you for your good comments.

Reviewer #2:

1. Response to comment: in "MTT" analysis please include a brief explanation of this method.

Response: We have revised this section. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed according to the protocol of the manufacturer to determine the proliferation of EPCs [7]

2. Response to comment: Two topics that could be discussed further regarding EPCs

Response: We have revised this section. EPCs are considered to be immature endothelial cells that can promote angiogenesis. The most widely accepted phenotypically defined EPC is the coexpression of the cell-surface markers CD34 and VEGFR2[20].

3. Response to comment: Pag 5 Line 23: EPCs are

Response: “are” was added.
4. Response to comment: Pag 5 line 47: Minor (upper case after dot)
Response: “Minor” was added.

5. Response to comment: Pag 8 line 29: add comma before “respectively”
Response: We have revised it.

6. Response to comment: Pag 9 line 27: That's (upper case)
Response: We have revised “that”.

7. Response to comment: Pag 15 line 37: Transwell
Response: We have revised it.

8. Response to comment: Pag 15 line 38: The cell migration (upper case after dot)
Response: We have revised it.

9. Response to comment: Bibliography, Ref 9: a page is lost.
Response: We have revised it. The lost page number is 151.

10. Response to comment: Figure 2C: scale is not clear.
Response: We have relabeled this figure. The scale is 100μm.

11. Response to comment: Figure 3A y 3C: missed scale
Response: We have revised it. “magnification ×200” and “magnification ×100” have been added in figure legend.
Special thanks to you for your good comments.

Added references:


